This review summarizes the current state of knowledge surrounding mortality rates, modes of death, and prognostic factors in HFPEF. Despite the lack of uniform reporting, the following conclusions ...

The section presents a review of diastolic congestive heart failure, commonly called HFpEF. Reviews of systolic congestive HF, or HFrEF, valvular heart disease, pulmonary hypertension and right HF ...

A gene therapy for heart failure with preserved ejection fraction (HFpEF), also known as diastolic heart failure, has shown ...

Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeutics. SRD-002 is a gene therapy utilizing an ...

Ninerafaxstat acts as a partial fatty acid oxidation inhibitor. Ninerafaxstat may fill an unmet need in HFpEF as it represents a unique mechanism of improving cardiac energetics. By shifting ...

The company has also received FDA approval to initiate LEVEL-2, a global Phase 3 study for TNX-103 in PH-HFpEF, with the first patient expected to be enrolled later this year. This study aims to ...